Nordic Lung Cancer Screening Software Market Size & Outlook, 2026-2034
Nordic Lung Cancer Screening Software Market Insights
- Reed Intelligence analysis indicates that the Nordic Lung Cancer Screening Software Market size, valued at USD 26.98 Million in 2025, is expected to expand to USD 83.73 Million by 2034.
- The Nordic market is forecasted to expand at a CAGR of 13.49% spanning 2026–2034.
- Cloud-Based held the leading position among Deployment segments in 2025, based on market size.
- On-Premise is projected to post the fastest growth rate, sustaining its position as the most attractive Deployment segment during the forecast horizon.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Nordic contributed 1.12% to the global Lung Cancer Screening Software Market size in 2025.
- By 2034, United States is forecasted to remain the largest global market for Lung Cancer Screening Software Market.
- In Europe, Germany is projected to capture the leading share of market size by 2034.
- Among Europe markets, Spain is expected to post the fastest growth, reaching USD 141.26 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 26.98 Million |
| Market Size In 2034 | USD 83.73 Million |
| Largest segment | Cloud-Based |
| Units | Revenue in USD Million |
| CAGR | 13.49% (2026-2034) |
| Segmnetation Covered | |
| Deployment |
|
| Application |
|
| Component |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Nordic Lung Cancer Screening Software Market Deployment 2026-2034 (USD Million)
| Deployment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cloud-Based | XX.x | XX.x | XX.x | 16.67 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| On-Premise | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Lung Cancer Screening Software Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nodule Detection | XX.x | XX.x | XX.x | 14.08 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Risk Assessment | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reporting Workflow Management | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Lung Cancer Screening Software Market Component 2026-2034 (USD Million)
| Component | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Software | XX.x | XX.x | XX.x | 15.03 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Services | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Lung Cancer Screening Software Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 13.31 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Imaging Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
